YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Allogene Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) produ…
Allogene Therapeutics ALLO incurred a second-quarter 2026 loss of 13 cents per share, narrower than the Zacks Consensus Estimate of a loss of 16 cents. Lower research and development (R&D) spending supported the narrower loss. In the year-…
(RTTNews) - Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company, announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to cemacabtagene ansegedleucel, or ce…
Shares of Allogene Therapeutics (ALLO [https://seekingalpha.com/symbol/ALLO]) rose on Wednesday after the U.S. Food and Drug Administration awarded the Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the compa…
Quick Read KYTX dropped 12% after JPMorgan trimmed its price target to $29, despite beating Q1 estimates and initiating a rolling BLA for miv-cel targeting a 2027 launch. BEAM slid 8% from a 52-week high and ALLO dropped 5%, while myasthen…
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Novo Nordisk saw a bump in its stock last week after reporting that its Wegovy weight-loss pill is…
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is among the best low priced stocks to get rich in 2026. On June 12, BofA started coverage on Avalo Therapeutics, Inc. (NASDAQ:AVTX) with a Buy rating and a price target of $35. According to the firm,…
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the small-cap stocks with potential to rise 1000 percent. The company's 2026 setup now rests on whether it can turn its off-the-shelf CAR T platform into clinical evidence across both can…
A month has gone by since the last earnings report for Allogene Therapeutics (ALLO). Shares have lost about 12.2% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue…
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the top penny stocks to buy in investors’ stock portfolio. On May 13, Allogene Therapeutics, Inc. (NASDAQ:ALLO) reiterated positive interim results in the ALPHA3 trial of cemacabtagene an…
* Allogene Therapeutics (ALLO [https://seekingalpha.com/symbol/ALLO]) said [https://seekingalpha.com/pr/20532710-allogene-therapeutics-announces-planned-ceo-succession] on Thursday that CEO David Chang will step down effective June 30 afte…
David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of DirectorsZachary Roberts, M.D., Ph.D., EVP, Research & Development and…
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune…
Key Points Interested in Allogene Therapeutics, Inc.? Here are five stocks we like better. ALPHA3 interim data for cema-cel showed a meaningful MRD clearance signal in first-line large B-cell lymphoma, with 58.3% clearance versus 16.7% in…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
Natera, Inc. (NASDAQ:NTRA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like.William Blair Initiates Natera (NTRA) With Outperform William Blair initiated coverage of Natera, Inc. (NASDAQ:NTRA) with an Outperform rati…
Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best biotech penny stocks to buy in 2026. On April 16, Allogene Therapeutics closed its underwritten public offering, raising $200.4 million in aggregate gross proceeds. The offering c…
Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best growth stocks under $10 to invest in. On April 21, Allogene Therapeutics received regulatory clearance to expand its pivotal Phase 2 ALPHA3 study of cemacabtagene ansegedleucel (c…
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 15, 2026, H.C. Wainwright lowered its price target on Allogene Therapeutics, Inc. (NASDAQ:ALLO) to $11 from $12 while maintaini…
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s stock registered a 22.39% growth from a year ago and a 53.04% percent decline year-to-date. Based on analyst consen…
* Allogene Therapeutics (ALLO) priced [https://seekingalpha.com/pr/20473296-allogene-therapeutics-announces-pricing-of-public-offering-of-common-stock] an underwritten public offering of 87.5M shares of its common stock at a price to the p…
(RTTNews) - Allogene Therapeutics, Inc. (ALLO) priced the previously announced $175 million public offering of 87.50 million shares at $2.00 per share. The offering is expected to close on or about April 16, 2026. Also, Allogene has grante…
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a price to the public of…
Shares of Allogene Therapeutics ALLO rose 12.5% on Monday after the company announced encouraging data from the planned interim futility analysis of the pivotal phase II ALPHA3 study, which evaluated its lead candidate, cema-cel, an off-th…
Sandisk Corp.’s (SNDK) shares surged 11.8% as the stock is set to join the Nasdaq 100 Index on April 20, 2026. Shares of Allogene Therapeutics Inc. (ALLO) climbed 12.5% following positive phase 2 clinical trial data of its blood cancer the…
(RTTNews) - Allogene Therapeutics Inc. (ALLO), a clinical-stage biotechnology company, on Monday, announced a proposed underwritten public offering of $175 million in shares of the company's common stock. The proceeds from the public offer…
STORY: Wall Street's main indexes rallied on Monday, with the Dow gaining more than six-tenths of a percent, the S&P 500 climbing 1% and the Nasdaq adding nearly one-and-a-quarter percent.After a muted start to the day, stocks picked up st…
AUSTIN, Texas, April 13, 2026--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics’ (NASDAQ: ALLO) interim futility analysis from its registrational…
Allogene Therapeutics, Inc. (NASDAQ:ALLO) secured a spot on our list of the best penny stocks set to explode.Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)? As of April 8, 2026, analyst sentiment toward Allogene Therapeu…
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the penny stocks with potential to rise 1000 percent. Allogene Therapeutics said on March 12, 2026, that its lead program, cemacabtagene ansegedleucel, or cema-cel, remains on track in th…
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the 10 most active penny stocks to buy.Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout On March 13, 2026, Biren Amin, an analyst at Piper S…
Allogene Therapeutics ALLO incurred a fourth-quarter 2025 loss of 17 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. In the year-ago period, the company had reported a loss of 28 cents. As the company lac…
Earnings Call Insights: Allogene Therapeutics (ALLO) Q4 2025 MANAGEMENT VIEW * CEO David Chang described 2026 as a “defining year” focused on “delivering meaningful clinical milestones with rigor and speed.” He emphasized that Allogene’s a…
Allogene Therapeutics logo Key Points Allogene expects an interim MRD futility analysis from the randomized ALPHA3 trial in April reporting top‑line MRD clearance in 24 patients (12 per arm) and high‑level safety, targeting a conservative…
Image source: The Motley Fool. DATE Thursday, March 12, 2026 at 5 p.m. ET CALL PARTICIPANTS Chief Executive Officer — David ChangChief Medical Officer — Zachary RobertsChief Financial Officer — Geoffrey Parker Need a quote from a Motley Fo…
Last Friday, all three Wall Street benchmark stock indexes registered weekly losses. The Dow Jones Industrial Average fell 2.89%, the S&P 500 declined 1.75% and the Nasdaq Composite slipped 0.59%. The downturn was largely due to a sharp su…